Introduction
Non-functioning pituitary macroadenoma (NFMA) can cause considerable morbidity due to pituitary dysfunction and pressure effects. Prevalence of pituitary adenoma is 80-100 cases per 100,000 of the population; of these NFMA accounts for 15-30%. Annual incidence is one per 100,000 of population¹ ² We present recent experience in managing NFMA at a single tertiary centre between January 2009 and Oct 2013.
Results
NFMAs represent the bulk of patients presenting with a pituitary tumour. The clinical presentation can vary widely from asymptomatic incidental finding to catastrophic pituitary apoplexy as seen in this series.
Majority of NFMAs require surgery. A select subset can be managed conservatively. However these patients require long-term follow-up to monitor for tumour growth.
Appropriate and timely surgery can be crucial in patients presenting with apoplexy and should be considered in those with neuro-ophthalmic signs.
Post-operative hormone replacement is required in significant proportion of patients.
Of the 63 patients with NFMA, 28 (44%) were females. Age ranged from 22 to 91 (mean-63).
The commonest presentations are shown below .
Prolactin levels ranged from 25 to 2536 mU/l (mean-394). Six patients (10%) were found hypothyroid at presentation. Pituitary MRI scan showed elevation or compression of optic chiasm in 55 patients (87%).
49
(78%) underwent endoscopic trans-sphenoidal hypophysectomy. Three patients (5%) required surgery for further tumour enlargement during follow-up. 
Hormone Replacement
Post-operative complications included transient diabetes insipidus (5/49; 10%), CSF leak (2/29; 4%) and haemorrhage (1/49; 2%).
Post-operatively, hormone replacement was required as shown below.
Patients with apoplexy had emergency surgery (n=2), elective surgery (n=4) and conservative management (n=2). Five patients had improved vision following surgery, while one patient undergoing surgery after a year had no visual recovery.
